Connect with me on LinkedIn!
Pioneering the Future of Regenerative Medicine
A Canadian/Hungarian/American researcher based in Bellingham, WA — bridging biochemistry, AI, and transformative cell therapies to redefine what's possible in modern medicine.
About
A Global Innovator at the Forefront of Medical Science
Rooted in a rich multicultural heritage spanning Canada, Hungary, and the United States, my career has been shaped by an unrelenting curiosity about the human body's capacity to heal. Based in Bellingham, WA, I operate at the global forefront of medical innovation — where cutting-edge science meets compassionate patient care.
My work centers on some of the most transformative therapies in modern medicine: Chimeric Antigen Receptor T-cell (CAR-T) treatments, cord blood applications, and the pioneering use of mesenchymal stem cells derived from Wharton's Jelly. Each of these modalities represents a paradigm shift in how we understand disease, immunity, and regeneration.
Underpinning everything is a deep foundation in biochemistry — the molecular language that connects scientific theory to clinical reality. This foundation enables me to ask the right questions, design rigorous experiments, and translate discovery into therapeutic impact.
Core Identity
Multicultural Heritage
Canadian · Hungarian · American
Based in Bellingham, WA
Global reach, Pacific Northwest roots
Biochemistry Foundation
Molecular science driving clinical innovation
Impact
Transformative Therapies That Redefine Patient Outcomes
My work centers on pioneering therapeutic approaches that harness the body's intrinsic healing capabilities. These advanced modalities represent a profound shift in how we combat disease and restore health, moving beyond conventional treatments.
CAR-T Cell Therapies
Engineering a patient's own immune cells to precisely target and destroy cancer, offering new hope for hematologic malignancies.
Cord Blood Stem Cells
Utilizing precious newborn stem cells for treating blood disorders, immune deficiencies, and unlocking regenerative potential.
Wharton's Jelly MSCs
Leveraging multipotent stem cells from umbilical cord tissue for their potent regenerative and immunomodulatory properties.
Specializations
Transformative Therapies That Redefine Patient Outcomes
From engineered immune cells to stem cell-derived biologics, my research portfolio spans the most promising frontiers in cell and gene therapy.
CAR-T Cell Therapy
Engineering patient-derived T-cells with chimeric antigen receptors to precisely target and eliminate malignant cells — a living drug unlike anything before it.
Cord Blood Applications
Harnessing the rich hematopoietic potential of umbilical cord blood to treat hematological disorders, immune deficiencies, and emerging regenerative indications.
Wharton's Jelly MSCs
Leveraging mesenchymal stem cells from umbilical cord Wharton's Jelly — a non-invasive, ethically uncontested source with exceptional immunomodulatory and regenerative properties.
Regulatory Expertise
Bridging Groundbreaking Science and Regulatory Reality
Holding a Master's in Biopharmaceutical Regulatory Affairs, I possess a rare dual fluency — deeply conversant in both the scientific language of cell biology and the regulatory architecture that governs therapeutic development. This expertise is not merely administrative; it is strategically essential.
Navigating the FDA's Center for Biologics Evaluation and Research (CBER), EMA pathways, and international equivalents requires precision and foresight. I work to ensure that innovative therapies are not only scientifically sound but also positioned for successful regulatory review and approval — accelerating the path from bench to bedside.

Bridging science and compliance is how promising therapies actually reach patients — regulatory mastery is as vital as scientific discovery.
Manufacturing Excellence
cGMP Cell Therapy Manufacturing: Where Quality Is Non-Negotiable
Extensive hands-on experience in current Good Manufacturing Practice (cGMP) cell therapy manufacturing ensures that every therapy developed meets the most rigorous standards of quality, safety, and consistency required for clinical and commercial deployment.
Quality Systems
Implementing robust QMS frameworks that govern every aspect of cell therapy production — from raw material qualification to final product release.
Process Validation
Designing and executing IQ/OQ/PQ validation protocols that demonstrate reproducibility and consistency across manufacturing runs.
Regulatory Documentation
Authoring Batch Manufacturing Records, SOPs, and deviation reports that satisfy domestic and international regulatory expectations.
Sterility & Safety
Maintaining aseptic conditions and environmental monitoring standards that protect product integrity and patient safety at every step.
Cutting-Edge Research
AI-Driven Reprogramming: The Next Frontier
Perhaps the most audacious dimension of my current research sits at the convergence of artificial intelligence and regenerative medicine — a frontier where computational power amplifies biological possibility.
iPSC Research
From Somatic Cells to Induced Pluripotent Stem Cells
I am currently leveraging AI to design artificial plasmids that incorporate the renowned Yamanaka transcription factors — Oct4, Sox2, and Klf4 — to reprogram somatic cells into induced pluripotent stem cells (iPSCs). This process, once a painstaking manual endeavor, is being radically accelerated through machine learning-guided vector design and optimization.
The implications are profound. iPSCs represent a virtually unlimited, patient-specific source of cells that can be differentiated into virtually any tissue type. By eliminating the ethical complexities associated with embryonic stem cells, iPSC technology opens an ethically clear pathway to personalized regenerative therapies.
From these iPSCs, we harvest exosomes — nanoscale extracellular vesicles that carry bioactive cargo including proteins, lipids, and RNA. These exosomes are emerging as powerful mediators of tissue repair, immune modulation, and intercellular communication, holding extraordinary potential in next-generation regenerative applications.
1
AI Plasmid Design
Machine learning optimizes Yamanaka factor delivery vectors
2
Somatic Reprogramming
Oct4, Sox2, Klf4 convert adult cells to iPSCs
3
Exosome Harvesting
iPSC-derived exosomes collected for therapeutic use
4
Regenerative Application
Exosomes deployed in targeted tissue repair therapies
The Yamanaka Factors
The Molecular Keys to Cellular Reprogramming
The Yamanaka transcription factors — originally discovered by Nobel Laureate Shinya Yamanaka — are the molecular master switches that unlock cellular pluripotency. AI-optimized delivery of these factors represents a leap forward in precision and efficiency.
Oct4
A master regulator of pluripotency, Oct4 maintains stem cell identity and suppresses differentiation-associated genes — the cornerstone of the reprogramming cocktail.
Sox2
Works in concert with Oct4 to maintain the transcriptional network governing self-renewal, ensuring reprogrammed cells retain genuine pluripotent characteristics.
Klf4
Enhances reprogramming efficiency by activating pluripotency genes and suppressing somatic cell identity — a critical amplifier in the transcription factor ensemble.
Patient Access
Making Innovation Accessible: Compassionate Use & Medical Tourism
Scientific excellence means little if transformative therapies remain out of reach for the patients who need them most. Beyond the laboratory, I am deeply committed to addressing unmet medical needs through two critical pathways: compassionate use requests and facilitated medical tourism.
Compassionate use programs — also known as expanded access — allow patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials. Navigating these regulatory pathways requires both scientific credibility and regulatory acumen, skills I bring to bear on behalf of patients who have exhausted conventional options.
Through medical tourism facilitation, I connect patients with internationally available regenerative treatments that may not yet be accessible in their home countries, ensuring they receive care that is both scientifically sound and ethically administered.
Mission & Vision
A Multifaceted Mission: Science, Access, and Impact
Through a multifaceted approach spanning laboratory research, regulatory strategy, manufacturing excellence, and patient advocacy, the mission is singular: to advance medical science in ways that generate tangible, positive impact on patient outcomes worldwide.
3
Therapy Platforms
CAR-T, cord blood, and Wharton's Jelly MSC applications
3+
Countries of Heritage
Canada, Hungary, and the United States — a truly global perspective
4
Yamanaka Factors
Oct4, Sox2, Klf4, and c-Myc in the original reprogramming cocktail
Let's Connect
Collaborate, Innovate, Transform
Whether you are a fellow researcher exploring synergies in regenerative medicine, a biotech leader seeking regulatory expertise, a clinician advocating for a patient in need of compassionate access, or an investor looking to fund the next generation of cell therapies — I welcome the conversation.
The challenges ahead in medicine are immense, but so is the opportunity. Together, we can push the boundaries of what's scientifically possible and bring those advances to the patients who need them most. Innovation does not happen in isolation — it thrives in collaboration, across borders, disciplines, and perspectives.
Areas of Collaboration
Research Partnerships
Joint studies in iPSC biology, exosome therapeutics, and CAR-T optimization
Regulatory Consulting
IND submissions, EMA pathways, and cGMP compliance strategy
Patient Advocacy
Compassionate use navigation and medical tourism facilitation
Investment & Funding
Advancing clinical-stage regenerative medicine programs